News
Dr. Yuxin Chen Received Peptide Application Special Award

Dr. Yuxin Chen Received Peptide Application Special Award

From July 4th to 6th, 2018, the15th Chinese International Peptide Sympossium was hold in Shenzhen. During the sympossium, Dr. Yuxin Chen, president of ProteLight Pharma, received the Peptide Application Special Awar for his outstanding contribution to peptide science.

10

2018

/

07

ProteLigt R & D Team was named as “Innovation and Entrepreneurship Team” of Jiangsu Province in 2017

ProteLigt R & D Team was named as “Innovation and Entrepreneurship Team” of Jiangsu Province in 2017

On December 27th, 2017, appraised by Jiangsu Province Personnel Work Leading Group and CPC Jiangsu Provincial Party Committee, ProteLight’s R & D team was finally named as “Innovation and Entrepreneurship Team” of Jiangsu Province in 2017, which is the only Noble Prize Winner type’s Innovation and Entrepreneurship Team in this appraisal.

29

2017

/

12

Congratulate to ProteLight for Being Identified as Hi-Tech Enterprise

Congratulate to ProteLight for Being Identified as Hi-Tech Enterprise

On December7th, 2017, through strict appraisal by relevant higher authorities that Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. was identified as Hi-Tech Enterprise, which strongly suggests that the government confirm ProteLight taking national category 1.1 new drug development as direction over the years, which is also an important signal of ProteLight’s technical level and products technology.

10

2017

/

12

ProteLight Pharma Held a Grand-breaking Ceremony of New Plant Construction

ProteLight Pharma Held a Grand-breaking Ceremony of New Plant Construction

On September 22th, 2017, the Grand-breaking Ceremony of ProteLight’s new plant construction opened, that locates at Xingao Road, Hi-Tech district, Jiangyin. The leaders of multiple departments of Jiangyin government and Dr. Yuxin Chen, chairman of Protelight’s board showed there. The new factory covers an area of 65,000 square meters, including production workshops, R&D centers and office buildings etc.

22

2017

/

09

ProteLight Pharma's Technical Consultant Received the Bruce Merrifield Award, the Most Prestigious Award in Polypeptide Research Field

ProteLight Pharma's Technical Consultant Received the Bruce Merrifield Award, the Most Prestigious Award in Polypeptide Research Field

During June 17th to 22th, 2017, the 25th American Peptide Symposium opened in Whistler, Canada, Dr. Robert Hodges, the technical consultant and shareholder of ProteLight Pharmaceuticals, received the most prestigious award in polypeptide research field, the Bruce Merrifield Award, for his outstanding lifetime achievement in peptide research, and his scientific creativity is the highest level in peptide field.

05

2017

/

07

ProteLight Signed at Jianying Economic and Trade Fair

ProteLight Signed at Jianying Economic and Trade Fair

On September 20th, Jiangyin Hi-Tech district government hold a conference with theme of constructing a national self-innovative demonstration area in South Jiangsu. Thirteen key and major projects that with large investment scale, high industrial level, and strong industry-driven singed on the conference. As a major project, ProteLight signed there, and President, Mr. YunChen made a speech on the conference.

26

2016

/

09

CCTV News reported ProteLight

CCTV News reported ProteLight

On August 9th, CCTV News reported Jiangyin Hi-Tech District and Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., as a high technology and pharmaceutical corporation, ProteLight develops well in the industrial environment of Jiangyin High-Tech District.

11

2016

/

08

Anti-infection 1.1 New Drug PL-5 is approved to be in Clinical Trial

Anti-infection 1.1 New Drug PL-5 is approved to be in Clinical Trial

On April 15th, CFDA announced on internet that anti-infection 1.1 new drug PL-5 of Jiangsu ProteLight Pharma was approved to be in clinical trial, which is the first antimicrobial peptide innovative drug in clinical trial in China. With characters of low toxicity, high efficiency and anti-drug resistant bacteria, PL-5 has a significant advantage of disinfecting “the super bacteria”, which is resistant to traditional antibiotics. Antimicrobial peptide PL-5 being in clinical trial can relieve the suffering of patients with skin infection.

19

2016

/

04

< 12345 >